LQDA vs TENX
LQDA: A biopharmaceutical company revolutionizing treatment for pulmonary hypertension using its proprietary PRINT particle engineering technology and treprostinil-based therapies. TENX: Tenax Therapeutics is a clinical-stage biotechnology company developing specialized therapies for pulmonary hypertension and other cardiopulmonary conditions.
Side-by-side fundamentals
| Metric | LQDA | TENX | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $36.35 | $1.63 | |
| Market cap | $3.3B | $61M | |
| P/E as of 2026-10-20 | 25.96 | n/a | |
| Net margin FY2025, SEC XBRL | -43.5% | n/a | |
| Operating margin FY2025, SEC XBRL | -32.5% | n/a | |
| ROE FY2025, SEC XBRL | -154.0% | -54.2% | TENX higher |
| ROA FY2025, SEC XBRL | -21.0% | -50.5% | LQDA higher |
| Revenue growth (YoY) FY2025, SEC XBRL | +1031.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +115.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.97 | 0.46 | |
| 1-year return as of 2026-10-20 close | +48.7% | -75.7% | LQDA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.